Drug Trial Radar · NCT02760433
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease
Last checked: Nov 20, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
368
Actual
Start
Jan 25, 2017
Primary completion
Sep 12, 2019
Study completion Oct 1, 2019
Sponsor
- Lead sponsor
- R-Pharm International, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Quintiles, Inc.; OCT Clinical Trials; Mene Research
- First posted
- May 3, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving, but not fully responding to treatment with an existing medication called a tumour necrosis factor alpha inhibitor The primary objective of this study was to evaluate the efficacy of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) relative to placebo in subjects with moderately to severely active rheumatoid arthritis (RA) inadequately controlled by TNF-α inhibitor (TNFi) therapy.
Conditions
- Rheumatoid Arthritis
Interventions
OlokizumabDrug
160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
PlaceboDrug
sodium chloride 0.9% solution provided as either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) ResponseTime frame: at Week 12
Locations
116 sites in 11 countries. Site status is shown where the registry gives one.
Arizona Arthritis & Rheumatology Associates, P.C.
Phoenix, Arizona
CHI St. Vincent Hot Springs
Hot Springs, Arkansas
Medvin Clinical Research
Covina, California
TriWest Research Associates, LLC
El Cajon, California
Saint Jude Heritage Medical Grp
Fullerton, California
С V Mehta MD Med Corp.
Hemet, California
Advanced Medical Research, LLC
Lakewood, California
Stanford University School of Medicine
Palo Alto, California
Riverside Medical Clinic
Riverside, California
East Bay Rheumatology Medical Group, Inc.
San Leandro, California
Inland Rheumatology Clinical Trials, Inc.
Upland, California
Denver Arthritis Clinic
Denver, Colorado
Javed Rheumatology Associates
Newark, Delaware
RASF - Clinical Research Center
Boca Raton, Florida
Suncoast Research Group LLC
Miami, Florida
Omega Research Consultants
Orlando, Florida
Family Clinical Trials, LLC.
Pembroke Pines, Florida
AdventHealth Medical Group, PA
Tampa, Florida
Institute of Arthritis Research
Idaho Falls, Idaho
University of Kansas Hospital
Kansas City, Kansas
Graves Gilbert Clinic
Bowling Green, Kentucky
The Arthritis & Diabetes Clinic, Inc.
Monroe, Louisiana
Klein and Associates, M.D., P.A.
Hagerstown, Maryland
The Center for Rheumatology and Bone Research
Wheaton, Maryland
Clinical Pharmacology Study Group
Worcester, Massachusetts
Glacier View Research Instutute-Rheumatology
Kalispell, Montana
Arthritis & Osteoporosis Associates, PA
Freehold, New Jersey
Lovelace Scientific Resources, Inc.
Albuquerque, New Mexico
NYU Langone Ambulatory Care
New York, New York
Medication Management, LLC
Greensboro, North Carolina
Cape Fear Arthritis Care
Leland, North Carolina
Carolina Arthritis Associates
Wilmington, North Carolina
Trinity Medical Group
Minot, North Dakota
Cincinnati Rheumatic Disease Study Group
Cincinnati, Ohio
STAT Research, Inc.
Dayton, Ohio
Clinical Research Source, Inc.
Perrysburg, Ohio
Arthritis Group
Philadelphia, Pennsylvania
Low Country Research Center
Charleston, South Carolina
Amarillo Center for Clinical Research
Amarillo, Texas
Austin Regional Clinic, P.A.
Austin, Texas
Showing 40 of 116 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.